Thermo Fisher Scientific Inc.
TMO
$466.70
-9.20%
Thermo Fisher Scientific Inc. is a global leader in providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents, operating within the Medical - Diagnostics & Research industry. The company is a dominant market player, distinguished by its integrated portfolio across four key segments—analytical technologies, specialty diagnostics, life sciences, and lab products/services—which creates a powerful platform serving the entire scientific research and healthcare continuum. The current investor narrative revolves around navigating a post-pandemic normalization in its core markets, with attention focused on its ability to sustain growth through strategic acquisitions, operational execution, and capitalizing on long-term secular trends in biopharma and diagnostics, amidst a backdrop of recent stock price volatility reflecting broader market concerns.…
TMO
Thermo Fisher Scientific Inc.
$466.70
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $606.71 and implied upside of +30.0% versus the current price.
Average Target
$606.71
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$373 - $607
Analyst target range
Analyst coverage data is limited in the provided set, showing only one analyst with an estimated EPS average of $36.24, which is insufficient to derive a meaningful consensus target price or recommendation distribution. The lack of broad analyst coverage suggests this data snapshot may be incomplete; however, the institutional ratings provided show a consistently bullish sentiment, with recent actions from major firms like Citigroup (upgrade to Buy), Keybanc (upgrade to Overweight), and sustained Buy/Overweight ratings from Barclays, Morgan Stanley, and Wells Fargo. The wide range of price targets is not available in the data, but the unanimous bullish stance from the listed institutions, coupled with recent upgrades, signals strong professional conviction in the company's long-term fundamentals despite recent stock price weakness.
Bulls vs Bears: TMO Investment Factors
The evidence presents a tense battle between strong underlying fundamentals and severe technical/ sentiment damage. The bull case is anchored in the company's financial fortress, stable margins, and the compelling discount embedded in its forward P/E multiple. The bear case is driven by the stock's dramatic underperformance, elevated trailing valuation, and the technical breakdown from its highs. Currently, the bearish technical momentum and valuation compression risk hold stronger near-term evidence, as reflected in the stock's -17.56% relative strength. The single most important tension in the investment debate is whether the company's robust free cash flow and operational execution can soon validate the forward earnings expectations (19.43x P/E), or if continued growth deceleration and sector headwinds will force a further de-rating of those forward multiples.
Bullish
- Robust Free Cash Flow & Financial Health: The company generates massive free cash flow of $6.293 billion TTM, providing immense flexibility for strategic M&A, buybacks, and dividends. A strong balance sheet with a debt-to-equity ratio of 0.765 and a current ratio of 1.89 underpins this financial fortress.
- Strong Institutional Conviction: Recent analyst upgrades from Citigroup and Keybanc to Buy/Overweight, alongside sustained bullish ratings from major firms, signal deep professional conviction in the long-term thesis despite recent price weakness. This institutional support provides a valuation floor.
- Attractive Forward P/E Valuation: The forward P/E of 19.43x represents a significant discount to the trailing P/E of 32.34x, indicating the market has priced in near-term earnings pressure and is positioned for a growth reacceleration. This forward multiple is reasonable for a market leader with 7.2% YoY revenue growth.
- Stable Profitability & Margin Resilience: Net margins have remained stable between 14.5% and 16.2% over the last four quarters, demonstrating the company's ability to maintain profitability in a post-pandemic normalization phase. Q4 2025 net margin of 16.17% shows operational discipline.
Bearish
- Severe Negative Momentum & Underperformance: The stock has significantly underperformed the market, with a 3-month decline of -14.89% and a relative strength of -17.56 versus the SPY over the same period. This persistent negative momentum, despite a recent bounce, indicates deep-seated selling pressure and sector-specific concerns.
- Elevated Trailing Valuation Multiples: A trailing P/E of 32.34x and an EV/EBITDA of 21.71x command a premium valuation that remains vulnerable to compression if growth decelerates further. The PEG ratio of 4.51 suggests the stock is expensive relative to its near-term growth profile.
- Revenue Growth Deceleration Post-Pandemic: While Q4 revenue grew 7.2% YoY, this represents a normalization from pandemic-era peaks. Sequential quarterly revenue volatility indicates lumpiness, and the company must prove it can sustain mid-single-digit growth organically in a normalized demand environment.
- High Dependence on M&A for Growth: As a mature market leader, Thermo Fisher's historical growth has been heavily fueled by strategic acquisitions. In a higher interest rate environment, the cost and availability of capital for large-scale M&A could pressure its primary growth engine, risking a slowdown.
TMO Technical Analysis
The stock is in a pronounced downtrend from its recent highs, trading at approximately 81.8% of its 52-week range based on a current price of $526.6 against a 52-week high of $643.99 and low of $385.46, positioning it significantly off its peak but not at deeply oversold levels. The 1-year price change of +23.18% masks severe recent weakness, as evidenced by a 3-month decline of -14.89% and a 6-month drop of -2.29%, indicating strong negative momentum that has reversed the longer-term gains. Recent momentum shows a stark divergence, with a 1-month surge of +13.32% suggesting a potential relief rally or short-term rebound attempt from deeply oversold conditions, contrasting sharply with the persistent negative trends over the last three and six months. Key technical support is anchored at the 52-week low of $385.46, while immediate resistance is at the recent peak and 52-week high of $643.99. A sustained move above the recent recovery high near $640 would signal a potential trend reversal, while a breakdown below the March 2026 low of $464.37 could open the path toward the 52-week low. The stock's beta of 0.972 indicates volatility roughly in line with the broader market, but its significant underperformance is highlighted by a relative strength of -17.56 versus the SPY over the last three months, suggesting idiosyncratic or sector-specific pressures driving its decline.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$385-$644
Price range past year
Annual Return
+8.1%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | -4.8% | +8.5% |
| 3m | -25.4% | +2.8% |
| 6m | -18.5% | +4.6% |
| 1y | +8.1% | +32.3% |
| ytd | -21.2% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth remains positive but has decelerated from pandemic-era peaks, with Q4 2025 revenue of $12.215 billion representing a 7.2% year-over-year increase; however, sequential quarterly revenue has shown volatility, moving from $10.364B in Q1 to a peak of $12.215B in Q4, indicating some quarterly lumpiness but an overall upward annual trajectory. The company is solidly profitable, with Q4 2025 net income of $1.975 billion and a net margin of 16.17%, supported by a gross margin of 37.95%; profitability metrics have been stable, with the net margin hovering between 14.5% and 16.2% over the last four quarters, demonstrating resilience in a normalized demand environment. The balance sheet is healthy with a debt-to-equity ratio of 0.765, a current ratio of 1.89 indicating strong short-term liquidity, and robust cash generation evidenced by trailing twelve-month free cash flow of $6.293 billion, providing ample financial flexibility for dividends, share buybacks, and strategic M&A.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 32.34x, while the forward P/E is significantly lower at 19.43x, indicating the market expects a substantial recovery in earnings growth over the next twelve months. Compared to sector averages implied by its own historical data, the current trailing P/E of 32.34x is below its 5-year historical peaks seen above 40x but above lows near 20x, placing it in a mid-to-upper range of its own historical band. The stock's price-to-sales ratio of 4.89x and EV/EBITDA of 21.71x further reflect a premium valuation typical for a market leader, but the discount of the forward P/E to the trailing multiple suggests the market has already priced in near-term earnings pressure and is looking toward a growth reacceleration.
PE
32.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher's primary financial risk is not insolvency—given its strong balance sheet (D/E 0.765) and massive FCF ($6.3B)—but rather valuation compression if it fails to meet growth expectations priced into its forward P/E of 19.4x. Revenue growth has decelerated to 7.2% YoY, and any further slowdown could trigger multiple contraction. Furthermore, the company's growth strategy is heavily reliant on accretive M&A; a prolonged period of high interest rates or a scarcity of suitable targets could impair its ability to sustain historical growth rates, pressuring the premium valuation.
Market & Competitive Risks: The stock trades at premium multiples (P/S 4.89x, EV/EBITDA 21.71x) and is highly susceptible to sector rotation out of healthcare/life sciences tools, especially if macroeconomic conditions deteriorate. Its beta of 0.97 indicates market-correlated volatility, but its severe recent underperformance (-17.56% vs. SPY over 3 months) suggests idiosyncratic risks are at play, such as concerns over biopharma funding or diagnostics demand normalization. Competitive disruption from newer, more agile players in specific niches could also erode its dominant market share over time.
Worst-Case Scenario: The worst-case scenario involves a combination of a deeper-than-expected biopharma downturn, failed integration of past acquisitions, and a broad market sell-off compressing growth stock multiples. This could lead to a re-rating toward its historical valuation lows, with the P/E multiple falling toward 20x on depressed earnings. The stock could realistically retest its 52-week low of $385.46, representing a downside of approximately -27% from the current price of $526.6. A break below that level could see losses extend toward -35%, aligning with the stock's recent max drawdown of -27.38%.
